Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
Korean J Pathol. 2012 Jun;46(3):226-232. English. Multicenter Study.
Sohn JH , Gong G , Kim KR , Kang CS , Lee YS , Kim JM , Jung WH , Suh KS .
Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. jhpath.sohn@samsung.com
The Cancer Registration Committee of the Korean Society of Pathologists, Seoul, Korea.
Department of Pathology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea.
The Breast Pathology Study Group, Seoul, Korea.
The Gynecological Pathology Study Group, Seoul, Korea.
Department of Pathology, The Catholic University of Korea School of Medicine, Seoul, Korea.
Department of Pathology, Chungnam National University School of Medicine, Daejeon, Korea.
Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
Abstract

BACKGROUND: Cancer registration in Korea has a longer than 30-years of history, during which time cancer registration has improved and become well-organized. Cancer registries are fundamental for cancer control and multi-center collaborative research. However, there have been discrepancies in assigning behavior codes. Thus, we intend to propose appropriate behavior codes for the International Classification of Disease Oncology, 3rd edition (ICD-O-3) for microinvasive tumors of the ovary and breast not only to improve the quality of the cancer registry but also to prevent conflicts. METHODS: As in series I, two pathology study groups and the Cancer Registration Committee of the Korean Society of Pathologists (KSP) participated. To prepare a questionnaire on provisional behavior code, the relevant subjects were discussed in the workshop, and consensus was obtained by convergence of opinion from members of KSP. RESULTS: Microinvasive tumor of the breast should be designated as a microinvasive carcinoma which was proposed as malignant tumor (/3). Serous borderline tumor with microinvasion of the ovary was proposed as borderline tumor (/1), and mucinous borderline tumor with microinvasion of the ovary as either borderline (/1) or carcinoma (/3) according to the tumor cell nature. CONCLUSIONS: Some issues should be elucidated with the accumulation of more experience and knowledge. Here, however, we present our second proposal.

Copyright © 2019. Korean Association of Medical Journal Editors.